warnings
WARNINGS Nursing Mothers: It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.
Hydroxyzine Pamoate
openFDA label record#
Cross-check layer: This is openFDA JSON-derived label data. Use the corresponding DailyMed SPL as the canonical label.
Verified complete openFDA source JSON
- Brand name
- Hydroxyzine Pamoate
- Generic name
- HYDROXYZINE PAMOATE
- Manufacturer
- Amneal Pharmaceuticals of New York LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- bc82aaaf-30c7-4afe-a908-d138ea1268ef
- SPL ID
- fef8a507-e0a1-43ca-89ae-dfaf46c44216
- Version
- 11
- Effective date
- 2026-06-11
- Source export date
- 2026-08-01
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-08-01/5cbbf4af8f4e275ec50931155b30ffa7322568b9af8a1c936a47f6d6774862fd/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- bdd1454d0606b622b70458a306b8a10d8a8787db06fd9f46e69c7f7a4524b630
- Import run
- 20260801T225920Z
- Imported at
- 2026-08-01 23:02:07
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 040156 | derived:openfda.application_number |
| application number | ANDA040156 | openfda.application_number | |
| brand name | Hydroxyzine Pamoate | openfda.brand_name | |
| generic name | HYDROXYZINE PAMOATE | openfda.generic_name | |
| manufacturer name | Amneal Pharmaceuticals of New York LLC | openfda.manufacturer_name | |
| ndc | package | 0115-1804-01 | openfda.package_ndc |
| ndc | package | 0115-1803-02 | openfda.package_ndc |
| ndc | package | 0115-1803-01 | openfda.package_ndc |
| ndc | package | 0115-1804-02 | openfda.package_ndc |
| ndc | product | 0115-1804 | openfda.product_ndc |
| ndc | product | 0115-1803 | openfda.product_ndc |
| ndc11 | package | 00115180402 | derived:openfda.package_ndc |
| ndc11 | package | 00115180401 | derived:openfda.package_ndc |
| ndc11 | package | 00115180301 | derived:openfda.package_ndc |
| ndc11 | package | 00115180302 | derived:openfda.package_ndc |
| rxcui | 995278 | openfda.rxcui | |
| rxcui | 995253 | openfda.rxcui | |
| spl id | fef8a507-e0a1-43ca-89ae-dfaf46c44216 | id | |
| spl set id | bc82aaaf-30c7-4afe-a908-d138ea1268ef | set_id | |
| unii | M20215MUFR | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature. Skin and Appendages: Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post-marketing reports. Anticholinergic: Dry mouth. Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System: QT prolongation, Torsade de Pointes. In post-marketing experience, the following additional undesirable effects have been reported: Body as a Whole: allergic reaction, Nervous System: headache, Psychiatric: hallucination, Skin and Appendages: pruritus, rash, urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.